Retrospective Descriptive Study of Platelet Transfusion in Patients With Palliative Hematologic Malignancies at the University Hospital of Besançon

NCT03814486 | Completed

• 1 other identifier: J Moracchini
• Study Type: observational
• Target: 119
• Locations: 1 country
• Sites: 1

Brief Summary

Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting. The purpose of this study was to describe retrospectively platelet transfusion in the six last few month of life of patients with hematologic malignancies at the CHU of Besançon (France) between 01/07/15 and 31/12/16.

Conditions

Platelet Transfusion; Palliative Care

Keywords

platelet transfusion; palliative care

Outcome Measures

Primary Outcomes (3)

• evaluate frequency of platelet transfusion at the end of life

  to calculate the number of platelet transfusion at the end of life. The number of platelet transfusion between 6 months and death are collected in each periods of 2 weeks to calculate the number of transfusion per patient during each 2 weeks.

  18 months (between 07/01/2015 and 12/31/2016)

• evaluate efficacy of prophylactic platelet transfusion at the end of life

  to calculate the platelet yield in percentage

  18 months (between 07/01/2015 and 12/31/2016)

• evaluate efficacy of non prophylactic platelet transfusion at the end of life

  to calculate the transfusional interval between 2 platelet transfusion in days

  18 month (between 07/01/2015 and 12/31/2016)

Secondary Outcomes (1)

• demographic characteristic

  18 months (between 07/01/2015 and 12/31/2016)

Study Arms (1)

patient transfused in platelet in the 6 last months of life

patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life

Other: descriptive

Interventions

descriptive OTHER

evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted

patient transfused in platelet in the 6 last months of life

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patient with hematological malignancies,transfused in platelet at least once in the last 6 months of life, hospitalised or follow up at the CHU of Besancon at least once and dead during the period of the study

You may qualify if:

• patient with hematological malignancies
• transfused in platelet at least once in the last 6 months of life
• hospitalised or follow up at the CHU of Besancon at least once
• dead during the period of the study

You may not qualify if:

• patient with other oncologic malignancies
• not transfused in platelet in the last 6 months of life
• never hospitalised or follow up at the CHU of Besancon
• alive

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Besancon: lead

Study Sites (1)

Moracchini

Besançon, 25000, France

Location

Related Publications (6)

• Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013 Feb;48(2):168-73. doi: 10.1038/bmt.2012.220. Epub 2012 Dec 3.

  PMID: 23208312 BACKGROUND

• Sherbeck JP, Boss RD. Ethical Questions about Platelet Transfusions at the End of Life. AMA J Ethics. 2016 Aug 1;18(8):764-70. doi: 10.1001/journalofethics.2016.18.8.ecas1-1608.

  PMID: 27550559 BACKGROUND

• Salacz ME, Lankiewicz MW, Weissman DE. Management of thrombocytopenia in bone marrow failure: a review. J Palliat Med. 2007 Feb;10(1):236-44. doi: 10.1089/jpm.2006.0126.

  PMID: 17298272 BACKGROUND

• Lassauniere JM, Bertolino M, Hunault M, Zittoun R, Verspieren P, Moh-Klaren J, Jaulmes D, Colombat P. Platelet transfusions in advanced hematological malignancies: a position paper. J Palliat Care. 1996 Spring;12(1):38-41.

  PMID: 8857246 BACKGROUND

• Boggs DR. Jehovah's Witnesses with leukemia. Hosp Pract (Off Ed). 1985 Mar 15;20(3):92, 94-5, 98 passim. doi: 10.1080/21548331.1985.11703015. No abstract available.

  PMID: 2414307 BACKGROUND

• Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney C, Roeland EJ. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018 Jun;26(6):1927-1931. doi: 10.1007/s00520-017-4023-y. Epub 2017 Dec 28.

  PMID: 29285557 RESULT

Study Officials

• regis aubry, ph

  Centre Hospitalier Universitaire de Besancon

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2019
• First Posted: January 24, 2019
• Study Start: July 1, 2017
• Primary Completion: July 1, 2018
• Study Completion: July 1, 2018
• Last Updated: January 30, 2019

Record last verified: 2018-12

Locations

FR (1)